Skip to contentS
Skye Bioscience, Inc.
S
SKYESkye Bioscience, Inc. Released Nov 6, 2020, after the close
10-Q filed Nov 6, 2020, 37 days after period end · 0001640334-20-002732
Q3 2020 · 10-Q
Revenue—
Net Income-$1.30M-$1.30MN/M vs Q3 2019N/M vs Q2 2020 No earnings release is on file for this quarter. Its figures came with the 10-Q.
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Skye Bioscience, Inc. · CIK 1516551 · Engraved from SEC EDGAR
EPS Diluted
-$0.01-$0.01N/M vs Q3 2019N/M vs Q2 2020 Operating Income-$1,538,220N/M Operating Cash Flowderived-$1,974,045N/M Free Cash Flowderived-$1,974,045— Filing lag
ended Sep 30, 2020 · filed Nov 6, 2020 · 37 d after period end